GILD · 10-Q · 2026Q3 · Full report

Cell Therapy Competition

GILEAD SCIENCES, INC. · 2026-10-30 · Importance 20 · Surprise 32

Cell Therapy product sales declined 18% to $355 million in the third quarter and 15% to $1.2 billion in the first nine months of 2026. Gilead attributed the decreases to lower demand reflecting ongoing competitive headwinds. The filing does not identify specific competitors or quantify share changes.

Key facts

• Gilead’s Cell Therapy sales decreased 18% to $355 million in Q3 2026 and 15% to $1.2 billion for the first nine months of 2026, primarily due to lower demand reflecting ongoing competitive headwinds. source